BNP Paribas Financial Markets Has $56,000 Stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

BNP Paribas Financial Markets trimmed its holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 65.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,914 shares of the company’s stock after selling 7,524 shares during the period. BNP Paribas Financial Markets’ holdings in CARGO Therapeutics were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of CRGX. Tower Research Capital LLC TRC boosted its position in shares of CARGO Therapeutics by 565.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock worth $84,000 after buying an additional 4,929 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of CARGO Therapeutics during the fourth quarter worth about $141,000. Invesco Ltd. acquired a new position in shares of CARGO Therapeutics during the fourth quarter worth about $165,000. Intech Investment Management LLC acquired a new position in shares of CARGO Therapeutics during the fourth quarter worth about $181,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of CARGO Therapeutics during the fourth quarter worth about $183,000. 93.16% of the stock is owned by institutional investors and hedge funds.

CARGO Therapeutics Price Performance

CRGX stock opened at $4.28 on Tuesday. The stock has a market capitalization of $197.35 million, a P/E ratio of -1.00 and a beta of 0.47. The business has a 50-day moving average of $4.23 and a 200-day moving average of $8.05. CARGO Therapeutics, Inc. has a fifty-two week low of $3.00 and a fifty-two week high of $25.45.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.